Koukoulis G K, Shin S S, Gould V E, Jao W, Gooch G T, Manderino G L, Rittenhouse H G, Tomita J T
Department of Pathology, Rush Medical College, Chicago.
Pathol Res Pract. 1990 Aug;186(4):439-49. doi: 10.1016/s0344-0338(11)80461-9.
Five hundred breast tissue samples from 404 cases were immunostained with A-80, a murine IgM Mab that recognizes a mucinous glycoprotein associated with exocrine differentiation. Samples included 196 primary breast carcinomas, 30 breast carcinoma metastases, 118 fibrocystic disease (FCD), and a further group of 84 samples of FCD from cases known to have breast carcinoma. These samples represented a broad spectrum of common and rare variants of carcinoma and FCD. Samples of fibroadenomas, lactating adenomas, cystosarcoma phylloides, gynecomastia, and normal breasts were similarly studied. The vast majority of carcinomas, 203/212 (95.7%) were immunoreactive; staining varied in extent and intensity, and was virtually unrelated to histologic type and to the presence or absence of recognizable glands. In samples including in-situ and infiltrating ductal or lobular carcinoma, reactivity was frequently stronger in the infiltrating components. No significant difference in reactivity between primary and metastatic carcinomas was noted. Of the group of 118 FCD, 27 were negative whereas 91 showed focal and weak staining. Seventy-two/84 FCD with associated carcinoma were immunostained; in 13 of those 72, staining was strong and extensive. Fibroadenomas, lactating adenomas, gynecomastia, and normal "resting" and lactating breast samples stained focally or not at all. Our findings indicate that Mab A-80 is an excellent immunohistochemical marker for the overwhelming majority of breast carcinomas whereas it marks weakly or not at all the majority of benign neoplasms and normal breast. Moreover, Mab A-80 recognizes a subset of FCD that includes proliferative variants associated with an increased incidence of carcinoma, and FCD in association with carcinoma. Questions regarding rare breast carcinomas that do not react with Mab A-80 remain unclear; yet, we believe that Mab A-80 is a highly promising marker of malignant and dysplastic breast epithelium.
用A - 80对404例患者的500份乳腺组织样本进行免疫染色，A - 80是一种鼠IgM单克隆抗体，可识别与外分泌分化相关的黏液糖蛋白。样本包括196例原发性乳腺癌、30例乳腺癌转移灶、118例纤维囊性疾病（FCD），以及另外84例已知患有乳腺癌的FCD样本。这些样本代表了癌和FCD的广泛常见及罕见变体。对纤维腺瘤、泌乳性腺瘤、叶状囊肉瘤、男性乳房发育症和正常乳腺样本也进行了类似研究。绝大多数癌，203/212（95.7%）呈免疫反应性；染色范围和强度各不相同，且实际上与组织学类型以及是否存在可识别的腺体无关。在包括原位癌和浸润性导管癌或小叶癌的样本中，浸润成分的反应性通常更强。原发性癌和转移性癌之间的反应性未发现显著差异。在118例FCD组中，27例为阴性，而91例显示局灶性和弱阳性染色。72/84例伴有癌的FCD进行了免疫染色；在这72例中的13例，染色强烈且广泛。纤维腺瘤、泌乳性腺瘤、男性乳房发育症以及正常“静止”和泌乳乳腺样本染色为局灶性或根本不染色。我们的研究结果表明，单克隆抗体A - 80是绝大多数乳腺癌的优秀免疫组化标志物，而它对大多数良性肿瘤和正常乳腺的标记较弱或根本不标记。此外，单克隆抗体A - 80识别FCD的一个亚组，该亚组包括与癌发生率增加相关的增殖性变体以及与癌相关的FCD。关于不与单克隆抗体A - 80反应的罕见乳腺癌的问题仍不明确；然而，我们认为单克隆抗体A - 80是恶性和发育异常乳腺上皮的极有前景的标志物。
